Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Acquisitions (2018 - 2024)

Ani Pharmaceuticals (ANIP) has disclosed Acquisitions for 3 consecutive years, with $8.2 million as the latest value for Q4 2024.

  • Quarterly Acquisitions changed N/A to $8.2 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $8.2 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $401.3 million for FY2024, N/A changed from the prior year.
  • Acquisitions hit $8.2 million in Q4 2024 for Ani Pharmaceuticals, down from $84.5 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $84.5 million in Q4 2021 to a low of $8.2 million in Q4 2024.